SCHEMBL4153390

SCHEMBL4153390

O=C(NCCCc1ccncc1)c1ccnc2[nH]c(-c3ccsc3)nc12

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.49
GSK3A P49840 2/20 0.49
RAD52 P43351 1/20 0.41
UHRF1 Q96T88 1/20 0.41
PBK Q96KB5 1/20 0.39
NAMPT P43490 1/20 0.38
MET P08581 1/20 0.38
HIF1A Q16665 1/20 0.37
CHEK1 O14757 2/20 0.37
CHEK2 O96017 2/20 0.37
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PKN1 Q16512 1/20 0.36
PKN2 Q16513 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4167099 0.94 GSK3B (0.55) GSK3BGSK3ARAD52UHRF1HIF1A
SCHEMBL4154111 0.90 GSK3B (0.50) GSK3BGSK3ANAMPTEPHX2
SCHEMBL4165122 0.89 GSK3B (0.45) GSK3BGSK3ARAD52UHRF1PBK
SCHEMBL4145775 0.86 GSK3B (0.57) GSK3BGSK3APBKMETHIF1A
SCHEMBL4149130 0.86 GSK3B (0.51) GSK3BGSK3APBKNAMPTMET
SCHEMBL4145768 0.85 GSK3B (0.56) GSK3BGSK3AHIF1ACHEK1CHEK2
SCHEMBL4157415 0.84 GSK3B (0.56) GSK3BGSK3ARAD52UHRF1NAMPT
SCHEMBL4147956 0.84 GSK3B (0.52) GSK3BGSK3ARAD52UHRF1NAMPT
SCHEMBL4148229 0.83 PBK (0.56) GSK3BPBK
SCHEMBL4147746 0.83 GSK3B (0.49) GSK3BGSK3ARAD52UHRF1PBK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885GSK3A 2/4885RAD52 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.